Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Kevin R. Bender, M.D./DBC Research Corporation
WARNING LETTER
•Kevin R. Bender, M.D./DBC Research Corporation•December 16, 2022

Kevin R. Bender, M.D./DBC Research Corporation – FDA Warning Letter, Dec 16, 2022

Record Details

The FDA issued a Warning Letter to Dr. Bender following an inspection from December 5-16, 2022, concerning the conduct of clinical investigations under the Bioresearch Monitoring Program. The inspection revealed violations of the Federal Food, Drug, and Cosmetic Act and 21 CFR Part 312.

The primary violations include failure to take adequate precautions to prevent theft or diversion of an investigational drug subject to the Controlled Substances Act (21 CFR 312.69) and failure to ensure the investigation was conducted according to the investigational plan (21 CFR 312.60). Specifically, 110 kits of investigational drug (b)(4), a Schedule III controlled substance, were reported missing due to customer/nonemployee theft. The drug was not stored in a securely locked, substantially constructed cabinet with limited access as required by regulations and Protocol (b)(4). The shipment was stored outside the designated locked cabinet in a locked room accessible to unauthorized individuals.

Dr. Bender's January 4, 2023, response acknowledged a breach in storage procedures and a comprehensive investigation, but the FDA deemed it inadequate. The response lacked sufficient details on how access to secure areas for investigational product would be limited to appropriate personnel and did not detail planned or completed training on responsible conduct of clinical trials or FDA compliance.

The FDA emphasized that these failures raise significant concerns about the protection of study subjects and the

Company
Kevin R. Bender, M.D./DBC Research Corporation
Inspection date
December 16, 2022
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • David C. Burrow (Director )
  • Miah Jung
View Company Profile

ID · 6175b24e-0c04-4f61-9b5a-502ee3d80c5c

Violation Codes3
21 CFR 31221 CFR 312.6921 CFR 312.60

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Kevin R. Bender, M.D./DBC Research Corporation
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.